Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Trials

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: Isatuximab SC-OBDS
Drug: Montelukast
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone
Drug: Carfilzomib

First Posted Date: 2024-04-10

Last Posted Date: 2025-05-18

Lead Sponsor: Sanofi

Target Recruit Count: 64

Registration Number: NCT06356571

Locations: 🇺🇸
Smilow Cancer Center at Yale-New Haven- Site Number : 8400020, New Haven, Connecticut, United States
🇺🇸
Millennium Oncology- Site Number : 8400011, Pembroke Pines, Florida, United States
🇺🇸
BRCR Global- Site Number : 8400008, Plantation, Florida, United States

and more 7 locations

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Stage III Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carfilzomib
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Drug: Sotorasib

First Posted Date: 2024-02-08

Last Posted Date: 2024-06-04

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 15

Registration Number: NCT06249282

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Alnuctamab
Drug: Pomalidomide
Drug: Daratumumab
Drug: Elotuzumab
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2024-01-31

Last Posted Date: 2024-05-31

Lead Sponsor: Celgene

Registration Number: NCT06232707

Locations: 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸
Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺
Local Institution - 0022, Waratah, New South Wales, Australia

and more 167 locations

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Etentamig
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Elotuzumab
Drug: Selinexor
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-12-06

Last Posted Date: 2025-05-15

Lead Sponsor: AbbVie

Target Recruit Count: 380

Registration Number: NCT06158841

Locations: 🇺🇸
University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Hospital - Phoenix /ID# 263326, Phoenix, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California, United States

and more 139 locations

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Carfilzomib

First Posted Date: 2023-11-30

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 492

Registration Number: NCT06152575

Locations: 🇫🇷
Hôpital NOVO, Pontoise, Val-d'oise, France
🇺🇸
Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States

and more 168 locations

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Extramedullary Multiple Myeloma
Primary Plasma Cell Leukemia

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: epirubicin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: bortezomib

First Posted Date: 2023-11-21

Last Posted Date: 2025-04-16

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 54

Registration Number: NCT06140966

Locations: 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Forimtamig
Drug: Daratumumab
Drug: Carfilzomib

First Posted Date: 2023-09-26

Last Posted Date: 2025-05-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 316

Registration Number: NCT06055075

Locations: 🇦🇺
Princess Alexandra Hospital Woolloongabba, Woolloongabba, Queensland, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 5 locations